查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1861922

生物製藥生物分離系統市場按產品類型、操作模式、材料類型、應用和最終用戶分類 - 全球預測（2025-2030 年）

Biopharmaceutical Bioseparation Systems Market by Product Type, Operation Mode, Material Format, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2030 年，生物製藥生物分離系統市場將成長至 243.8 億美元，複合年成長率為 9.54%。

關鍵市場統計數據
基準年 2024 141億美元
預計年份：2025年 154.2億美元
預測年份 2030 243.8億美元
複合年成長率 (%) 9.54%

展望未來，先進的生物分離系統將以其高效性、擴充性和合規性革新生物製藥工作流程。

本執行摘要介紹了生物分離系統在現代生物製藥生產中的現狀和戰略發展方向。下游純化領域已從專注於孤立的宣傳活動操作發展成為兼顧產量、純度和操作靈活性的綜合性學科。同時，業界正在採用更多模組化和一次性架構，以加快生產週期並降低資本投入，同時滿足日益嚴格的產品品質和製程驗證監管要求。因此，相關人員在重新評估長期以來在批次處理和連續處理靈活性之間的技術權衡，以適應日益多樣化的分子類型和生產規模。

分析顛覆性創新和製程整合如何重新定義下游生物製造的產量、純度和永續性

生物分離系統領域正經歷著變革性的轉變，這不僅重塑了技術藍圖，也改變了整個價值鏈的商業性行為。層析法介質的進步、膜技術的改進以及可靠的圓盤式和臥螺式離心平台的出現，正在突破技術的界限，實現高通量操作和更高效的雜質去除。同時，一次性技術正從小眾應用領域走向核心生產過程和下游純化步驟，從而減輕了多產品生產設施的清潔驗證負擔，並縮短了生產前置作業時間。這些變化並非純粹的技術變革，而是反映了營運模式的重組，旨在提高靈活性、加速臨床試驗進程並降低專案層面的風險。

評估美國關稅至2025年及其對生物製造領域採購、供應連續性和下游經濟的影響

美國關稅將於2025年之前生效，為全球生物分離供應鏈帶來了顯著的複雜性，其影響涵蓋採購慣例到資本規劃等各個方面。關稅調整大幅提高了進口模組、備件和專用耗材的到岸成本，促使製造商重新評估其供應商選擇標準、合約條款和庫存策略。在需要單一來源組件來確保工藝流程檢驗的情況下，關稅相關的成本波動正在加速關於雙重採購、關鍵供應商近岸外包以及重新設計關鍵子系統以減少對受關稅影響的進口產品的依賴等問題的討論。

透過對產品類型、應用領域、最終用戶和操作模式進行深度細分分析，指導生物分離領域的投資重點。

細分市場趨勢分析揭示了不同產品類型、應用、最終用戶和操作模式所帶來的獨特機會和限制因素，這些因素共同決定了投資重點和實施路徑。產品系列涵蓋離心、層析法、薄膜過濾和一次性系統。離心進一步細分為臥螺離心機、碟片式離心機和管式離心機，選擇依據原料特性及澄清能力需求。層析法產品依模式分類，包括親和性、疏水交互作用層析、離子交換層析、混合模式層析和尺寸排除層析。親和親和性產品包括一些特殊形式，例如固定化金屬親和性、凝集素親和性和層析和蛋白A親和性，這些產品針對特定的生物分子類別。膜過濾包含微過濾、奈米過濾和超過濾方法，選擇依據孔徑要求和通量目標。一次性系統涵蓋一次性層析法和一次性過濾，可實現快速部署並降低多條產品線交叉污染的風險。

美洲、歐洲、中東、非洲和亞太地區的區域趨勢將影響基礎設施投資和跨境供應鏈策略。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的技術應用、監管合規和供應鏈配置產生了顯著影響。在美洲，生物製藥製造中心的集中佈局和成熟的供應商生態系統支援了複雜多產品生產設施和連續生產流程的早期應用，而密集的服務供應商網路則有助於快速驗證和試運行。在歐洲、中東和非洲地區，多樣化的管理體制以及對品質和環境合規的高度重視，推動了對節能營運和下游加工先進廢棄物管理的投資。在亞太地區，產能的快速擴張與優先考慮成本競爭力解決方案和可擴展的一次性部署的本地化製造舉措相結合，同時區域政策獎勵正在推動生物製藥及其配套基礎設施的本土化生產。

企業趨勢分析：生物分離供應商的夥伴關係、技術差異化、場地最佳化與競爭定位

生物分離供應商生態系統中的企業策略正在融合產品創新、服務拓展和商業性合作，以深化客戶關係並減少實施過程中的阻力。領先的設備和耗材供應商正透過專有化學技術、先進的樹脂技術和自動化能力實現差異化，同時投資於提供遠端監控、預測性維護和生命週期分析的數位化平台。與契約製造、生物服務公司和儀器供應商建立策略合作夥伴關係，使供應商能夠提供整合硬體、耗材和製程支援的承包解決方案，從而打造更具吸引力的商業性提案。這種解決方案化趨勢降低了買方整合風險，並加快了複雜下游應用實現價值的速度。

旨在加快營運韌性、降低純度成本並促進各層級模組化和連續生物分離技術應用的實用建議

產業領導者可以採取一系列切實可行的舉措，從不斷發展的生物分離技術中獲得營運和策略效益。首先，優先考慮資本投資的模組化，以便將新的層析法裝置、膜分離系統和離心模組整合到現有系統中，最大限度地減少對檢驗流程和公用設施的影響。這種方法可以降低實施風險，並允許根據產品平臺需求分階段進行現代化改造。其次，制定採購策略，透過尋找替代供應商、確保關鍵耗材的目標安全庫存以及簽訂包含績效指標和緊急條款的合作籌資策略協議，來平衡成本、前置作業時間和關稅風險。這些措施將增強企業應對地緣政治和物流衝擊的能力。

採用穩健的調查方法，結合針對性的初步訪談、技術文獻綜述和多面向資料檢驗，以檢驗產業趨勢。

本報告的調查方法結合了針對技術領導者、工程師和採購專業人員的定向訪談、對技術文獻和監管指南的系統性回顧，以及嚴謹的多源資料三角驗證流程，以支援研究觀察結果。主要研究旨在揭示實際實施中的挑戰、供應商績效特徵以及供應鏈的實際調整，而次要分析則將這些發現與已發表的技術研究、供應商文件和公開的監管材料進行整合和背景分析。這種三角驗證確保了關於技術能力和採用促進因素的論點至少透過兩個獨立的證據來源得到檢驗。

簡明扼要的結論，綜合分析了技術轉型、供應風險以及對推動生物分離領域營運轉型的相關人員的策略影響。

總之，生物分離系統正處於轉折點，技術創新、營運模式和地緣政治因素相互交織，重新定義下游製造策略。離心、層析法、薄膜過濾和一次性解決方案之間的相互作用，正在創造更豐富的架構選擇；連續加工的興起，迫使製造商重新思考生命週期成本、控制和供應鏈韌性。區域差異和關稅趨勢進一步要求在採購和場地設計方面採取更細緻入微的方法，而將技術差異化與服務和數位化能力相結合的供應商策略，將日益決定專案的成功執行。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 一次性層析法系統的興起旨在減少交叉污染並提高生產靈活性。
  • 推出連續下游處理平台，可實現生物分離過程中的無縫整合和高通量處理。
  • 整合先進的製程分析技術，用於即時監測煉油過程和產品品質屬性
  • 開發用於下一代單株抗體純化的高容量、高選擇性膜層析法
  • 應用數位雙胞胎建模和人工智慧技術最佳化生物分離程式參數和產量
  • 採用模組化、可攜式生物處理撬裝設備可實現生物分離製程的快速規模化生產，並減少設施佔地面積。
  • 更重視永續性，採用可再生層析法介質和環保清洗再生通訊協定
  • 新興的蛋白A替代品和新型親和性和配體可降低成本並提高病毒清除率
  • 單一途徑切向流過濾技術的進步可提高生物製藥生產中濃縮和過濾過程的效率
  • 監管機構強調品質源自於設計 (QbD) 框架，以確保生物製藥純化過程中的穩健控制策略。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 生物製藥生物分離系統市場（依產品類型分類）

  • 離心分離系統
    • 臥螺離心機系統
    • 碟片式離心機系統
    • 管式碗離心機系統
  • 層析法系統
    • 親和層析法
      • 固定化金屬親和層析法
      • 凝集素親和層析法
      • 蛋白A親和性和層析法
    • 疏水交互作用層析法
    • 離子交換層析法
    • 混合模式層析法
    • 尺寸排阻層析法
  • 薄膜過濾系統
    • 過濾系統
    • 奈米過濾系統
    • 超過濾系統

9. 生物製藥生物分離系統市場（依操作模式分類）

  • 批量處理
  • 連續加工
    • 多柱層析法
    • 灌注治療

第10章 生物製藥生物分離系統市場（依材料類型分類）

  • 可重複使用類型
  • 一次使用
    • 伽瑪射線輻照流道
    • 預滅菌組件

第11章 生物製藥生物分離系統市場（按應用分類）

  • 細胞澄清
  • 純化/最終純化
  • 蛋白質純化
    • 酵素純化
    • 單株抗體
    • 胜肽純化
    • 重組蛋白純化
  • 疫苗生產
  • 病毒純化

第12章 生物製藥生物分離系統市場（依最終用戶分類）

  • 學術和研究機構
  • 生物製藥公司
  • 生物服務
  • 契約製造組織

第13章 生物製藥生物分離系統市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 生物製藥生物分離系統市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國生物製藥生物分離系統市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • Asahi Kasei Corporation
    • Bio-Rad Laboratories, Inc.
    • GEA Group Aktiengesellschaft
    • Merck KGaA
    • Tecan Trading AG
    • Sartorius AG
    • Shimadzu Corporation
    • Tosoh Bioscience LLC
    • Alfa Laval AB
Product Code: MRR-521BAA36EA6F

The Biopharmaceutical Bioseparation Systems Market is projected to grow by USD 24.38 billion at a CAGR of 9.54% by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 14.10 billion
Estimated Year [2025] USD 15.42 billion
Forecast Year [2030] USD 24.38 billion
CAGR (%) 9.54%

A forward-looking introduction to advanced bioseparation systems transforming biopharmaceutical workflows with efficiency, scalability, and regulatory alignment

This executive summary introduces the current state and strategic contours of bioseparation systems as they intersect with modern biopharmaceutical manufacturing. The downstream purification domain has matured from a focus on isolated unit operations to an integrated discipline that balances throughput, purity, and operational agility. In parallel, the industry is negotiating tighter regulatory expectations for product quality and process validation while adopting more modular and single-use architectures to accelerate campaign turnaround and lower capital intensity. Consequently, stakeholders are re-evaluating long-standing engineering trade-offs between batch flexibility and continuous processing to align with increasingly varied molecule types and production scales.

The introduction frames the central themes that recur across this report: technological convergence across centrifugation, chromatography, membrane filtration, and single-use modalities; shifting application demand driven by vaccines, monoclonal antibodies, and novel biologics; and an evolving competitive environment that places a premium on service integration, digital enablement, and supply resilience. By establishing this context, the report prepares operators, technology providers, and procurement leaders to interpret subsequent sections that detail segmentation insights, regional dynamics, tariff effects, and corporate strategies. The aim is to equip decision-makers with a concise synthesis of trends and practical lenses for evaluating capital projects, vendor selection, and process modernization initiatives.

Analysis of disruptive technological advancements and process integrations that redefine throughput, purity, and sustainability in downstream biomanufacturing

The landscape for bioseparation systems is experiencing transformative shifts that are reshaping both technology roadmaps and commercial behavior across the value chain. Advances in chromatographic media, higher-performing membranes, and more reliable disc and decanter centrifuge platforms have expanded the technical envelope, enabling higher throughput operations and more robust impurity clearance. Simultaneously, single-use technologies have migrated from niche applications into primary production and downstream polishing steps, reducing cleaning validation burdens and shortening lead times for multi-product facilities. These shifts are not purely technical; they reflect an operational reorientation toward flexibility, faster time-to-clinic, and lower program-level risk.

Equally important, process intensification trends-especially the move toward continuous processing and multi-column chromatography-are altering plant layouts and capital allocation decisions. Continuous frameworks promise steadier product quality and more efficient resin utilization, yet they demand stronger controls infrastructure and supply chain hygiene. In response, vendors and end users are co-developing integrated offerings that bundle equipment, consumables, and digital process control to reduce implementation complexity. Finally, digitalization is serving as an accelerant: real-time analytics, model-based control, and predictive maintenance are improving uptime and enabling lifecycle management of purification assets. Together, these changes create new strategic imperatives for technology adoption, training, and cross-functional alignment between process development and manufacturing operations.

Assessment of United States tariffs through 2025 and implications for sourcing, supply continuity, and downstream process economics in biomanufacturing

United States tariff measures enacted through 2025 have introduced a material layer of complexity for global bioseparation supply chains, with implications that extend from procurement practices to capital planning. Tariff adjustments have increased the effective landed cost of imported modules, spare parts, and specialized consumables, creating an imperative for manufacturers to reassess supplier selection criteria, contract terms, and inventory strategies. In contexts where single-source components are essential to validated processes, tariff-related cost volatility has accelerated conversations around dual sourcing, nearshoring of key suppliers, and redesign of critical subsystems to reduce dependency on tariff-impacted imports.

Operationally, the tariffs have elevated the importance of total cost of ownership analysis and of scenario planning for supply interruptions. Manufacturers are prioritizing supplier resilience and lead-time certainty, often accepting modestly higher component prices in exchange for assured delivery and technical support. In the capital projects domain, procurement teams are expanding pre-award scrutiny to include tariff exposure and logistics risk, while engineering groups evaluate alternative designs that permit the substitution of non-tariffed materials without compromising validation. On the vendor side, equipment suppliers are responding through revised commercial models, localization of manufacturing nodes, and strategic stock positioning to smooth customers' procurement cycles and to preserve service levels. Ultimately, tariffs have reinforced the strategic value of supply chain transparency, flexible sourcing networks, and collaborative contracting practices between equipment makers and biomanufacturers.

Deep segmentation insights that illuminate product types, application areas, end users, and operation modes to guide targeted investments in bioseparation

Segment-level dynamics reveal differentiated opportunities and constraints across product types, applications, end users, and operation modes that together shape investment priorities and adoption pathways. Product families span centrifugation systems, chromatography systems, membrane filtration systems, and single-use systems, with centrifugation further differentiated into decanter, disc stack, and tubular bowl platforms that are selected based on feedstock characteristics and clarifier capacity needs. Chromatography offerings split across affinity, hydrophobic interaction, ion exchange, mixed-mode, and size exclusion modalities, while affinity options include specialized formats such as immobilized metal affinity, lectin affinity, and Protein A affinity that target discrete biomolecule classes. Membrane filtration encompasses microfiltration, nanofiltration, and ultrafiltration approaches that are chosen according to pore-size requirements and throughput targets. Single-use systems extend across single-use chromatography and single-use filtration, which offer rapid deployment and reduced cross-contamination risk for multi-product lines.

Applications drive equipment choices in nuanced ways, with cell clarification, polishing and final purification, protein purification, vaccine production, and virus purification each imposing distinct performance and validation constraints. Within protein purification, subsegments like enzyme purification, monoclonal antibodies, peptide purification, and recombinant protein purification create divergent demands for resolution, capacity, and consumable lifetimes. End users span academic and research institutes, biopharmaceutical companies, bioservices, and contract manufacturing organizations, each bringing different volume profiles, regulatory rigor, and service expectations that inform vendor engagement models. Operation mode is another critical vector: batch processing remains the default for many legacy systems and small-batch production, whereas continuous processing-encompassing multi-column chromatography and perfusion processing-appeals to organizations seeking higher utilization and consistent product quality. When these segmentation layers are viewed together, they reveal that optimal technology selection is context-dependent and that vendors who can align modular product families with application-specific service offerings will have a competitive edge in meeting diverse customer needs.

Regional dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific shaping infrastructure investment and cross-border supply strategies

Regional dynamics materially influence technology adoption, regulatory navigation, and supply chain configuration across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, concentrated centers of biologics manufacturing and a mature supplier ecosystem support complex multi-product facilities and early adoption of continuous processing, while a dense service-provider network facilitates rapid validation and commissioning. Europe, Middle East & Africa exhibit heterogeneous regulatory regimes and a strong emphasis on quality and environmental compliance, prompting investments in energy-efficient operations and advanced waste management for downstream processes. Asia-Pacific combines rapid capacity expansion with localized manufacturing initiatives that prioritize cost-competitive solutions and scalable single-use deployments, and regional policy incentives are encouraging in-country production of biologics and their supporting infrastructure.

These regional variations have operational consequences: procurement teams calibrate sourcing strategies to local trade conditions and logistical realities, process development groups tune validation strategies to local regulatory expectations, and corporate leaders balance centralized design standards with regional customization to meet site-specific requirements. Cross-border collaboration and knowledge transfer remain essential levers for multinational programs, and the most effective approaches marry global technical standards with locally optimized supply and service arrangements.

Corporate analysis highlighting partnerships, technology differentiation, footprint optimization, and competitive positioning among bioseparation vendors

Corporate strategies within the bioseparation vendor ecosystem reflect a blend of product innovation, services expansion, and commercial partnerships intended to deepen customer relationships and reduce implementation friction. Leading equipment and consumable providers are differentiating through proprietary chemistries, advanced resin technologies, and automation capabilities while also investing in digital platforms that offer remote monitoring, predictive maintenance, and lifecycle analytics. Strategic partnerships with contract manufacturers, bioservices firms, and instrumentation suppliers enable vendors to deliver turnkey solutions that bundle hardware, consumables, and process support into more attractive commercial propositions. This trend toward solutionization mitigates buyer integration risk and shortens time-to-value for complex downstream deployments.

In parallel, companies are optimizing manufacturing footprints to improve delivery timelines and to manage tariff exposure, and some are creating regional assembly hubs or local sourcing agreements to enhance responsiveness. Competitive positioning increasingly depends on the ability to offer end-to-end validation support, robust technical training programs, and flexible commercial models such as equipment-as-a-service or reagent subscription arrangements. The cumulative effect is a market where technical differentiation is necessary but insufficient; vendors must also demonstrate reliable supply chains, expert services, and pragmatic pathways for clients to migrate from legacy processes to intensified or single-use approaches.

Actionable recommendations to accelerate operational resilience, reduce cost-to-purity, and enable adoption of modular and continuous bioseparation across tiers

Industry leaders can pursue a set of pragmatic actions to realize operational and strategic benefits from evolving bioseparation technologies. First, prioritize modularity in capital investments so that new chromatographic skids, membrane trains, or centrifugation modules can be integrated with minimal disruption to validated flows and utilities. This approach reduces implementation risk and enables staged modernization aligned with product pipeline needs. Second, develop sourcing strategies that balance cost, lead time, and tariff exposure by qualifying alternate suppliers, holding targeted safety stocks for critical consumables, and negotiating collaborative supply agreements that include performance metrics and contingency clauses. These measures strengthen resilience against geopolitical and logistical shocks.

Third, accelerate capability building in digital process control and analytics to support intensified and continuous operations. Training programs that upskill operators and process engineers in model-based control and real-time release concepts will shorten the learning curve and preserve product quality during transitions. Fourth, adopt flexible commercial models with vendors-such as pay-per-use for single-use disposables or bundled service contracts-to align cash flow with utilization rates and to lower barriers to technology adoption. Finally, foster cross-functional governance between process development, manufacturing, regulatory affairs, and procurement to ensure that technical choices are economically sensible, regulatory-compliant, and operationally executable. These recommendations create a coherent roadmap for deploying advanced bioseparation capabilities while mitigating execution risk.

Robust research methodology combining targeted primary interviews, technical literature review, and multi-source data triangulation to validate industry trends

The research methodology underpinning this report combines targeted primary interviews with technical leaders, engineers, and procurement professionals, a structured review of technical literature and regulatory guidance, and a rigorous multi-source data triangulation process to corroborate observations. Primary engagements were designed to surface practical implementation challenges, vendor performance characteristics, and real-world supply chain adaptations, while secondary analysis synthesized published technical studies, supplier documentation, and publicly available regulatory materials to contextualize those findings. Triangulation ensured that claims about technology capabilities and adoption drivers were validated through at least two independent evidence streams.

Where appropriate, the methodology also included scenario analysis to explore the operational implications of tariff shifts and supply chain disruptions, and sensitivity checks to identify assumptions that materially affect strategic conclusions. The report acknowledges limitations related to proprietary performance data and rapidly evolving supplier roadmaps; therefore, readers should interpret vendor capability statements alongside the practical validation exercises described in the methodology. Transparency in method and selective use of corroborated primary evidence underpin the report's conclusions and recommendations.

Concise conclusion synthesizing strategic implications for stakeholders navigating technological change, supply risks, and operational transformation in bioseparation

In conclusion, bioseparation systems are at an inflection point in which technological advances, operational models, and geopolitical forces converge to redefine downstream manufacturing strategy. The interplay between centrifugation, chromatography, membrane filtration, and single-use solutions is producing richer architectural choices, and the rise of continuous processing is compelling manufacturers to rethink lifecycle costs, controls, and supply resilience. Regional differences and tariff dynamics further compel nuanced approaches to sourcing and footprint design, while vendor strategies that combine technical differentiation with services and digital capabilities will increasingly determine execution success.

For stakeholders, the practical takeaway is clear: align capital and procurement strategies with a prioritized set of technical objectives, invest in workforce capabilities to manage intensified processes, and pursue supplier relationships that embed risk mitigation and service depth. Doing so will enable organizations to capture the benefits of higher productivity, improved product quality, and faster program timelines while managing the operational complexities introduced by rapid technological and market change.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growth of single-use and disposable chromatography systems to reduce cross contamination and improve manufacturing flexibility
  • 5.2. Adoption of continuous downstream processing platforms for seamless integration and higher throughput in bioseparation
  • 5.3. Integration of advanced process analytical technology for real-time monitoring of purification and product quality attributes
  • 5.4. Development of high-capacity and selective membrane chromatography for next-generation monoclonal antibody purification
  • 5.5. Implementation of digital twin modeling and artificial intelligence for optimizing bioseparation process parameters and yields
  • 5.6. Shift toward modular and portable bioprocessing skids enabling rapid scale-up and facility footprint reduction in bioseparation
  • 5.7. Increasing focus on sustainability through recyclable chromatographic media and eco-friendly cleaning and regeneration protocols
  • 5.8. Emergence of protein A alternatives and novel affinity ligands to decrease costs and improve viral clearance efficiency
  • 5.9. Advancements in single-pass tangential flow filtration to streamline concentration and diafiltration steps in biologics manufacturing
  • 5.10. Regulatory emphasis on quality by design frameworks ensuring robust control strategies for biopharmaceutical purification processes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopharmaceutical Bioseparation Systems Market, by Product Type

  • 8.1. Centrifugation Systems
    • 8.1.1. Decanter Centrifuge Systems
    • 8.1.2. Disc Stack Centrifuge Systems
    • 8.1.3. Tubular Bowl Centrifuge Systems
  • 8.2. Chromatography Systems
    • 8.2.1. Affinity Chromatography
      • 8.2.1.1. Immobilized Metal Affinity Chromatography
      • 8.2.1.2. Lectin Affinity Chromatography
      • 8.2.1.3. Protein A Affinity Chromatography
    • 8.2.2. Hydrophobic Interaction Chromatography
    • 8.2.3. Ion Exchange Chromatography
    • 8.2.4. Mixed-Mode Chromatography
    • 8.2.5. Size Exclusion Chromatography
  • 8.3. Membrane Filtration Systems
    • 8.3.1. Microfiltration Systems
    • 8.3.2. Nanofiltration Systems
    • 8.3.3. Ultrafiltration Systems

9. Biopharmaceutical Bioseparation Systems Market, by Operation Mode

  • 9.1. Batch Processing
  • 9.2. Continuous Processing
    • 9.2.1. Multi-Column Chromatography
    • 9.2.2. Perfusion Processing

10. Biopharmaceutical Bioseparation Systems Market, by Material Format

  • 10.1. Multi-Use
  • 10.2. Single-Use
    • 10.2.1. Gamma-Irradiated Flow Paths
    • 10.2.2. Presterilized Assemblies

11. Biopharmaceutical Bioseparation Systems Market, by Application

  • 11.1. Cell Clarification
  • 11.2. Polishing & Final Purification
  • 11.3. Protein Purification
    • 11.3.1. Enzyme Purification
    • 11.3.2. Monoclonal Antibodies
    • 11.3.3. Peptide Purification
    • 11.3.4. Recombinant Protein Purification
  • 11.4. Vaccine Production
  • 11.5. Virus Purification

12. Biopharmaceutical Bioseparation Systems Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Biopharmaceutical Companies
  • 12.3. Bioservices
  • 12.4. Contract Manufacturing Organizations

13. Biopharmaceutical Bioseparation Systems Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopharmaceutical Bioseparation Systems Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopharmaceutical Bioseparation Systems Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Agilent Technologies, Inc.
    • 16.3.3. Asahi Kasei Corporation
    • 16.3.4. Bio-Rad Laboratories, Inc.
    • 16.3.5. GEA Group Aktiengesellschaft
    • 16.3.6. Merck KGaA
    • 16.3.7. Tecan Trading AG
    • 16.3.8. Sartorius AG
    • 16.3.9. Shimadzu Corporation
    • 16.3.10. Tosoh Bioscience LLC
    • 16.3.11. Alfa Laval AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 3. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY OPERATION MODE, 2024 VS 2030 (%)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY OPERATION MODE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MATERIAL FORMAT, 2024 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MATERIAL FORMAT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. AFRICA BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASEAN BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. GCC BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. BRICS BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. G7 BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. NATO BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DECANTER CENTRIFUGE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DECANTER CENTRIFUGE SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DECANTER CENTRIFUGE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DECANTER CENTRIFUGE SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DECANTER CENTRIFUGE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DECANTER CENTRIFUGE SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DISC STACK CENTRIFUGE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DISC STACK CENTRIFUGE SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DISC STACK CENTRIFUGE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DISC STACK CENTRIFUGE SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DISC STACK CENTRIFUGE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DISC STACK CENTRIFUGE SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY TUBULAR BOWL CENTRIFUGE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY TUBULAR BOWL CENTRIFUGE SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY TUBULAR BOWL CENTRIFUGE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY TUBULAR BOWL CENTRIFUGE SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY TUBULAR BOWL CENTRIFUGE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY TUBULAR BOWL CENTRIFUGE SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY LECTIN AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY LECTIN AFFINITY CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY LECTIN AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY LECTIN AFFINITY CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY LECTIN AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY LECTIN AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN A AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN A AFFINITY CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN A AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN A AFFINITY CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN A AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN A AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MIXED-MODE CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MIXED-MODE CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MIXED-MODE CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MIXED-MODE CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MIXED-MODE CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MIXED-MODE CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MICROFILTRATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MICROFILTRATION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MICROFILTRATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MICROFILTRATION SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MICROFILTRATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MICROFILTRATION SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY NANOFILTRATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY NANOFILTRATION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY NANOFILTRATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY NANOFILTRATION SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY NANOFILTRATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY NANOFILTRATION SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ULTRAFILTRATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ULTRAFILTRATION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ULTRAFILTRATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ULTRAFILTRATION SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ULTRAFILTRATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ULTRAFILTRATION SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY OPERATION MODE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY OPERATION MODE, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BATCH PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BATCH PROCESSING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BATCH PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BATCH PROCESSING, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BATCH PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BATCH PROCESSING, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-COLUMN CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-COLUMN CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-COLUMN CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-COLUMN CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-COLUMN CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-COLUMN CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PERFUSION PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PERFUSION PROCESSING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PERFUSION PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PERFUSION PROCESSING, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PERFUSION PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PERFUSION PROCESSING, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MATERIAL FORMAT, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MATERIAL FORMAT, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-USE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-USE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-USE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 159. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 161. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GAMMA-IRRADIATED FLOW PATHS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GAMMA-IRRADIATED FLOW PATHS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 163. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GAMMA-IRRADIATED FLOW PATHS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GAMMA-IRRADIATED FLOW PATHS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 165. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GAMMA-IRRADIATED FLOW PATHS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GAMMA-IRRADIATED FLOW PATHS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 167. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRESTERILIZED ASSEMBLIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRESTERILIZED ASSEMBLIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 169. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRESTERILIZED ASSEMBLIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRESTERILIZED ASSEMBLIES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 171. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRESTERILIZED ASSEMBLIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRESTERILIZED ASSEMBLIES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 173. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 175. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CELL CLARIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CELL CLARIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 177. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CELL CLARIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CELL CLARIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 179. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CELL CLARIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CELL CLARIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 181. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY POLISHING & FINAL PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY POLISHING & FINAL PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 183. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY POLISHING & FINAL PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY POLISHING & FINAL PURIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 185. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY POLISHING & FINAL PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY POLISHING & FINAL PURIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 187. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, 2025-2030 (USD MILLION)
  • TABLE 189. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 191. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 193. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 195. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ENZYME PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ENZYME PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 197. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ENZYME PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ENZYME PURIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 199. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ENZYME PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ENZYME PURIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 201. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 203. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 205. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 207. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PEPTIDE PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PEPTIDE PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 209. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PEPTIDE PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PEPTIDE PURIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 211. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PEPTIDE PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PEPTIDE PURIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 213. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY RECOMBINANT PROTEIN PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY RECOMBINANT PROTEIN PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 215. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY RECOMBINANT PROTEIN PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY RECOMBINANT PROTEIN PURIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 217. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY RECOMBINANT PROTEIN PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY RECOMBINANT PROTEIN PURIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 219. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 221. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 223. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 225. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VIRUS PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VIRUS PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 227. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VIRUS PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VIRUS PURIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 229. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VIRUS PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VIRUS PURIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 231. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 233. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 235. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 237. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 239. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 241. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 243. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 245. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOSERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOSERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 247. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOSERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOSERVICES, BY GROUP, 2025-2030 (USD MILLION